Proof of Concept Study Evaluating BP1.3656 in Patients With Fatigue Following Ischemic Stroke

Bioprojet

Status and phase: Terminated; Phase 2

Conditions: Fatigue

Treatments: Drug: BP1.3656

Study type: Interventional

Funder types: Other

Identifiers

NCT05240560

2020-006006-23 (EudraCT Number)

P20-04 / BP1.3656

Details and patient eligibility

About

Multicenter, randomized, double blind, parallel-group, placebo-controlled proof of concept study evaluating efficacy and safety of BP1.3656 in patients with fatigue following ischemic stroke.

Enrollment: 5 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Males or females 18 years old or more;
• Diagnosis of ischemic stroke at least one month and not more than six months prior to screening;
• Persistent fatigue since the stroke with a score ≥ 50 across all domains of the Multidimensional Fatigue Inventory (MFI-20);
• Modified Rankin Score (mRS) < 3;
• Capability to participate in all study tests according to the investigator;
• Patient must voluntarily express a willingness to participate in this study, sign and date an informed consent prior to any study specific procedure;
• Females of child-bearing potential must have a negative pregnancy test performed at the screening and randomization visits and use a medically accepted effective method of birth control, agree to continue this method for the duration of the study up until three weeks after last treatment intake.

Exclusion criteria

• Any identified etiology for fatigue other than stroke (except post-stroke depression) according to the investigator;
• History of psychosis;
• Current severe psychiatric disorder, e.g. schizophrenia, bipolar disorder, severe depression, or organic brain syndrome preventing the patients from completing study assessments;
• Patients at risk of suicide according to the investigator;
• Major cognitive disorders, dementia according to the investigator;
• History of epilepsy or seizures disorder;
• History of alcohol or drugs (i.e. cannabis, cocaine, amphetamines or opioids) (ab)use/dependence within the 12 months prior to screening or with a positive drug test at screening;
• Glomerular filtration rate <60 mL/min/1.73m² according to Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula;
• Clinically significant cardiovascular abnormalities (including clinically relevant ECG abnormalities) or, clinically significant hematological, neurological, endocrine abnormalities, severe hepatic impairment or Liver Function Tests (ASAT, ALAT) > 3 ULN, or abnormal clinical laboratory results (in most cases > 3ULN);
• Other active clinically significant illness, infection, acid-related gastric disorder, or neoplastic pathology within the last 3 years (patients with fully cured non-melanoma skin cancer or in-situ carcinoma of the cervix are eligible) which could interfere with the study conduct or counter-indicate the study treatments or place the patient at risk during the trial or compromise his/her study participation.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

5 participants in 2 patient groups, including a placebo group

BP1.3656

Experimental group

Description:

1 tablet of 30 microgram (µg), 60µg or 90µg of BP1.3656 per day

Treatment:

Drug: BP1.3656

Placebo

Placebo Comparator group

Description:

1 tablet of matching placebo per day

Treatment:

Drug: BP1.3656